Semaglutide: what it is and what the evidence says
A molecule associated with the GLP-1 pathway, studied for its relationship with appetite control, satiety and glucose regulation. It is a long-acting GLP-1 analog, approved as a medicine for type 2 diabetes, weight management, and cardiovascular risk reduction.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
Metabolism is not a single lever. Talk about metabolic compounds usually collapses three separate mechanisms into one word. Appetite regulation is one. How well cells respond to insulin is another, and largely independent of the first. Mobilizing stored fat is a third. A compound may act on one and leave the other two untouched, so knowing which one is the difference between understanding a molecule and reciting its name.
What it is studied for
Appetite control, metabolic regulation.
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
Human evidence of the highest level. The phase 3 STEP program showed sustained weight losses of 15 to 17% at 68 weeks versus placebo, and the SELECT trial, with more than 17,000 participants, also showed fewer major cardiovascular events in people with obesity and without diabetes. FLOW (2024) and ESSENCE (2025) added benefit in the kidney and the liver.
The limitation that matters most
The benefit holds while treatment continues, and when it stops a good part of the weight comes back; a fraction of what is lost is lean mass and digestive effects are very common. The best very long-term maintenance strategy still needs to be defined, as does the frequency of rare effects such as the optic nerve injury the EMA added in 2025. In early Alzheimer's disease, the EVOKE trials (2026) showed no benefit.
Regulatory status
Approved by the FDA and the EMA for type 2 diabetes (Ozempic, Rybelsus) and for weight management (Wegovy, including adolescents from age 12). The FDA adds cardiovascular risk reduction (2024), chronic kidney disease with type 2 diabetes, and metabolic steatohepatitis with fibrosis (2025), as well as the Wegovy tablet (December 2025) and a higher-strength presentation (March 2026). The EMA authorized Kayshild for steatohepatitis in March 2026. WADA does not prohibit it and keeps it in its Monitoring Program, also for 2027.
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
Digestive effects are the most common, at the start and with each adjustment. The pancreas, gallbladder, hydration, and muscle mass are monitored, and it is contraindicated with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
It is a prescription medicine, and your doctor manages the indication, the adjustment, and the follow-up, all the more so if you have diabetes under treatment, a history of pancreatitis, or pregnancy plans.
What this page cannot give you
A reference page can take you this far. You know what Semaglutide is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a Certificate of Completion with a verifiable certificate ID, a Progress Tracker to follow how you are doing, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeReferences
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
Some title in this list contains a figure, because that is how the study was published and we reproduce titles verbatim: trimming them would make the citation impossible to verify. A title is not a protocol. What amount suits a particular person is decided by a professional who knows their case, never by the headline of a trial.
- Once-Weekly Semaglutide in Adults with Overweight or Obesityhuman N Engl J Med · 2021 · PMID 33567185 →
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trialhuman Lancet · 2021 · PMID 33667417 →
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trialhuman JAMA · 2021 · PMID 33755728 →
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trialhuman Nat Med · 2022 · PMID 36216945 →
- Once-Weekly Semaglutide in Adolescents with Obesityhuman N Engl J Med · 2022 · PMID 36322838 →
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabeteshuman N Engl J Med · 2023 · PMID 37952131 →
- Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials Metabolism · 2024 · PMID 39305981 →
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for Semaglutide or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is Semaglutide?
A molecule associated with the GLP-1 pathway, studied for its relationship with appetite control, satiety and glucose regulation. It is a long-acting GLP-1 analog, approved as a medicine for type 2 diabetes, weight management, and cardiovascular risk reduction. It is studied within the area of metabolic.
Is there human evidence for Semaglutide?
Human evidence of the highest level. The phase 3 STEP program showed sustained weight losses of 15 to 17% at 68 weeks versus placebo, and the SELECT trial, with more than 17,000 participants, also showed fewer major cardiovascular events in people with obesity and without diabetes. FLOW (2024) and ESSENCE (2025) added benefit in the kidney and the liver.
Is it approved by any health agency?
Approved by the FDA and the EMA for type 2 diabetes (Ozempic, Rybelsus) and for weight management (Wegovy, including adolescents from age 12). The FDA adds cardiovascular risk reduction (2024), chronic kidney disease with type 2 diabetes, and metabolic steatohepatitis with fibrosis (2025), as well as the Wegovy tablet (December 2025) and a higher-strength presentation (March 2026). The EMA authorized Kayshild for steatohepatitis in March 2026. WADA does not prohibit it and keeps it in its Monitoring Program, also for 2027.
What is the dose of Semaglutide?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what Semaglutide is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.